That's understandable. The coverage ranges from breathless enthusiasm to dire warnings, with not much room in between for a clear-eyed explanation of what these medications actually are, what the science says about how well they work, and what getting them safely actually involves.
This is that explanation.
The experience most people describe on GLP-1 medications is not fighting hunger , it is feeling genuinely less hungry. The medication changes the hormonal signals that drive appetite rather than asking you to override them.
What weight loss injections actually are
Weight loss injections belong to a class of medications called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1 , a hormone your body already produces naturally in the gut after you eat. It does several things: it signals to your brain that you've had enough, it slows the rate at which food moves through your stomach, and it reduces the amount of glucagon (a hormone that raises blood sugar) your pancreas releases.These medications mimic that hormone. When you inject them once a week, they activate the same receptors your body's own GLP-1 activates, producing a sustained version of those effects: a quieter appetite, a stronger feeling of fullness, and less preoccupation with food.
The two medications most commonly discussed in the UK are:
Wegovy (semaglutide), activates GLP-1 receptors. The first of the modern high-efficacy weight loss injections to be widely available. Approved by NICE in 2023 and available on the NHS in restricted circumstances.
Mounjaro (tirzepatide), activates both GLP-1 and GIP receptors simultaneously. GIP is a second gut hormone that works synergistically with GLP-1, producing greater appetite suppression than GLP-1 alone. Approved for weight management in the UK in 2024.
Both are injected subcutaneously, usually in the abdomen, thigh, or upper arm, once a week. You inject at home, rotating the site each week. The pens are pre-filled and use very fine needles , most people find the injection itself barely noticeable.
How they work: the hunger biology nobody explained to you
The reason these medications work so differently from dieting comes down to what they actually change. Dieting changes what you put in your mouth. GLP-1 medications change the hormonal signals telling your brain whether to be hungry in the first place.When you restrict calories, your body responds by raising ghrelin (the hormone that drives hunger) and lowering leptin (the hormone that signals fullness). These changes persist for months to years after the diet ends. Research published in the New England Journal of Medicine found that one year after a calorie-restricted diet, hunger-driving hormones were still significantly elevated and appetite ratings were still higher than before the diet started. This is why willpower fails , you are physiologically hungrier than you were before you started.
GLP-1 medications interrupt this cycle at the source. They directly suppress ghrelin, enhance satiety signalling, and act on the hypothalamus, the part of the brain that regulates hunger. The result , which almost everyone who takes them describes in the same way , is that food noise goes quiet. The persistent background preoccupation with what to eat, when to eat, and how much you already ate simply reduces. You get hungry, you eat, you feel full, and you stop thinking about food. It sounds simple because, for once, it is.
The changes that happen on GLP-1 treatment go beyond the scale: appetite and food noise reduce early, weight follows, and metabolic markers , blood sugar, cholesterol, blood pressure , improve over the course of treatment.
What the data actually says
How much weight do people lose?
The clinical trial results are genuinely significant by the standards of weight loss medicine. In SURMOUNT-1, the phase 3 trial for tirzepatide published in the New England Journal of Medicine in 2022, participants without diabetes lost an average of 22.5% of their body weight over 72 weeks at the 15mg dose. Between 50% and 57% of participants at higher doses lost 20% or more of their body weight. For context: this level of weight loss was previously only achievable through bariatric surgery.In the STEP-1 trial for semaglutide, participants lost an average of 14.9% of body weight over 68 weeks. In SURMOUNT-5, the first direct head-to-head comparison published in the New England Journal of Medicine in 2025, tirzepatide produced 20.2% weight loss versus 13.7% with semaglutide at maximum tolerated doses over 72 weeks.
Real-world supervised data goes further. Published data from a UK supervised cohort of over 125,000 members shows 24% average weight loss at 12 months, compared to 16% in clinical trials of the same medication. The supervised model, with ongoing dose management and personalised plans, consistently outperforms the trial benchmark.
It's not just weight
The data on what else changes alongside weight is the part that often surprises people. GLP-1 medications were originally developed for type 2 diabetes, and their effects on metabolic health go well beyond the scale.Published outcome data from supervised UK cohorts shows 100% reversal of pre-diabetes HbA1c, 72% improvement in cholesterol, and a 6.5% reduction in systolic blood pressure. The SELECT trial, which followed 17,604 adults with cardiovascular disease and obesity for nearly 40 months, found that semaglutide reduced heart attacks, strokes, and cardiovascular death by 20% compared to placebo.
Many people also report changes they were not expecting: that the obsessive relationship with food that drove comfort eating or binge episodes simply quietens. Published data shows 94% improvement in binge eating and 74% improvement in depression scores in supervised cohorts. The medication is not treating mental health directly , but the reduction in food noise and the shift in body weight and energy appear to carry psychological downstream effects.
What about side effects?
Side effects are real and worth knowing about before you start. The most common are gastrointestinal: nausea, constipation, diarrhoea, sometimes vomiting. They happen because the medication slows gastric emptying, which is the same mechanism that reduces appetite. The body adjusting to slower digestion is what causes the nausea, particularly in the first few weeks and after each dose increase.The reassuring thing is how they change over time. Published data from supervised UK cohorts shows nausea declining from 35% to 8% over 12 months, constipation from 33% to 10%, and headaches from 28% to 5%. The adjustment period is real, but it is not permanent. Most people find that slowing down the dose escalation, eating smaller portions, avoiding high-fat foods on injection day, and staying hydrated makes a significant difference.
Rarer side effects include gallbladder issues and, in some cases, acute pancreatitis. In clinical trials, serious adverse events were at rates similar to placebo. The MHRA monitors these medications continuously through the Yellow Card reporting scheme and updates product information when new signals emerge. The overall picture is that these are well-characterised medications with an extensive safety dataset.
The relationship with food changes on GLP-1 treatment, not through restriction or willpower, but because the hormonal signals driving hunger and food preoccupation are directly reduced. Most people describe eating less simply because they want less.
Are they worth it?
This is the honest answer: for people who are clinically eligible, meet the eligibility criteria, and access treatment through a properly supervised provider, the evidence strongly suggests yes.The weight loss achievable with these medications was previously only possible through bariatric surgery. The metabolic benefits, including blood sugar, cholesterol, and blood pressure improvements, reduce the risk of the long-term conditions that cause the most harm at population level. Nine in ten people who have used GLP-1 treatment through supervised UK providers say they would recommend it.
The caveat that matters most is the without proper support one. When people access GLP-1 medications without supervision, without dose management, and without any lifestyle support, outcomes are worse. Data suggests that two-thirds of lost weight can return within a year of stopping medication when it is used without any wraparound support. The medication works better , and the outcomes last longer , when it is part of supervised care with ongoing monitoring, rather than a pen posted through a letterbox with no follow-up.
How to access them safely in the UK
NHS access
Tirzepatide (Mounjaro) was approved by NICE for NHS use in 2024 and began rolling out through specialist weight management services from 2025. Access is highly restricted: NICE criteria require a BMI of 35 or above (or 32.5 if you are of South Asian, Chinese, or other at-risk background), plus at least one weight-related health condition. Wegovy is available via specialist NHS services for similar criteria. Most people access weight loss injections privately.Around 2.5 million people a month were accessing GLP-1 medications privately in the UK at the end of 2025, according to data published in the Pharmaceutical Journal. A YouGov poll commissioned by the National Pharmacy Association estimated 3.3 million UK adults will use weight loss injections in 2026.
What to look for in a private provider
The key difference between providers is whether treatment is supervised by a specialist. The General Pharmaceutical Council requires online pharmacies to independently verify weight and BMI rather than relying on self-reported data, and to carry out individual clinical assessment before prescribing. A BBC investigation in June 2025 found two pharmacies that allowed patients to falsify health information to obtain prescriptions — this is precisely what proper clinical assessment is designed to prevent.
Licensed UK weight loss injection pens carry a UK marketing authorisation number on the packaging. Purchasing from unverified sources , including social media, beauty salons, and unlicensed websites , carries serious safety risks, including counterfeit products containing unknown substances.
Red flags to avoid
- No clinical assessment required before prescribing.
- No BMI verification , just a questionnaire you fill in yourself.
- Prices significantly below the market rate for licensed medications.
- Products sold through social media, beauty salons, or unverified websites.
- No follow-up or monitoring offered after initial prescribing.
The MHRA dismantled the UK's first illicit weight loss injection factory in Northampton in October 2025, seizing over 2,000 counterfeit pens. UK Border Force seized approximately 18,300 illegal weight loss and diabetes medications at the border between January 2024 and June 2025. Counterfeit products have been found to contain insulin rather than semaglutide, causing hypoglycaemic shock and hospitalisation. The risk is not theoretical. Verify the GPhC register before using any online pharmacy.
For eligible patients, specialist-led tirzepatide prescribing through Voy includes dose escalation support, clinical monitoring, and discreet home delivery.
Quick answers
What is the difference between Mounjaro and Wegovy?
Both are once-weekly injections for weight management. Wegovy contains semaglutide and activates GLP-1 receptors. Mounjaro contains tirzepatide and activates both GLP-1 and GIP receptors simultaneously, which produces greater appetite suppression. In the first direct head-to-head trial (SURMOUNT-5, NEJM 2025), tirzepatide produced 20.2% weight loss versus 13.7% with semaglutide at maximum tolerated doses over 72 weeks. Both are effective; tirzepatide currently shows the greater average weight loss in clinical data.How long do you have to take them?
Weight loss injections are treatments for a chronic condition, not a course with a defined end point. Obesity is a metabolic condition involving hormonal and neurological dysregulation. When you stop taking the medication, ghrelin rises, satiety hormones fall, and appetite returns to approximately where it was before. Published data shows weight regain after stopping medication, which is consistent with how other chronic conditions work , you would not stop statins and expect your cholesterol to stay low. The appropriate duration of treatment is a clinical conversation, not a default assumption of short-term use.Will I lose muscle as well as fat?
Some lean mass loss occurs with any significant weight loss, including on GLP-1 treatment. Tirzepatide produces proportionally less lean mass loss than semaglutide in the clinical data. The practical mitigation is adequate protein intake (most adults on GLP-1 treatment need to be deliberate about protein, since appetite reduction can result in eating too little of it) and resistance exercise, which signals muscle preservation. Supervised providers guide on both.Are weight loss injections safe?
When prescribed following a proper clinical assessment and obtained from a GPhC-registered, CQC-regulated provider, licensed GLP-1 medications have an extensive safety record across tens of thousands of clinical trial participants and millions of real-world users. In the SELECT trial of 17,604 adults, serious adverse events were less frequent in the semaglutide group than in the placebo group. The safety question that matters most is whether the product is licensed and the prescribing is regulated , not whether the medication class has risks, which all medications do.How much do weight loss injections cost?
Private prescribing for Mounjaro in the UK typically runs from approximately £150 to £250 per month depending on dose and provider. Wegovy pricing is in a similar range. NHS access is free for eligible patients but highly restricted. Significant underpricing from unverified sources is a red flag, not a bargain.
AD Sources
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1. New England Journal of Medicine, 2022. N=2,539. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. STEP-1. New England Journal of Medicine, 2021.
• Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. SURMOUNT-5. New England Journal of Medicine, 2025. N=751. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. SELECT. New England Journal of Medicine, 2023. N=17,604.
• Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine, 2011.
• Voy outcome data: JMIR, 2025 (N=125,000+). 24% average weight loss; 100% quality of life improvement; 35% discontinuation reduction.
• Voy outcome data: Diabetes Obesity and Metabolism, 2025. 100% HbA1c reversal; 72% cholesterol improvement.
• Voy outcome data: Cureus, 2025. Nausea 35% to 8%; constipation 33% to 10%; headaches 28% to 5% over 12 months.
• MHRA. Warns of unsafe fake weight loss pens. GOV.UK. https://www.gov.uk/government/news/mhra-warns-of-unsafe-fake-weight-loss-pens
• MHRA. Urges public to avoid illegal online weight-loss medicines. GOV.UK, December 2025. https://www.gov.uk/government/news/mhra-urges-public-to-avoid-illegal-online-weight-loss-medicines-this-new-year
• GPhC. Weight management medicines and services review. April 2026. https://www.pharmacyregulation.org
• NICE. TA936: Tirzepatide for managing overweight and obesity. 2024. https://www.nice.org.uk/guidance/ta936
• Pharmaceutical Journal. Everything you need to know about GLP-1s for weight loss. February 2026.
.png)
No comments